Sarepta pays StrideBio $48M for preclinical gene therapies

Sarepta is set to pay $48 million upfront to work with StrideBio on gene therapies. The deal gives Sarepta exclusive licenses to four CNS targets plus an option to pay a further $42.5 million to add another four targets to the deal.